chartexchange

BillionToOne: 3 Key Takeaways for Long-Term Investors

The Motley Fool | Nov 15, 2026 12:37 PM EST

On its third quarter of 2026 earnings call, held on Nov. 4, 2026, BillionToOne (NASDAQ:BLLN) raised its full-year 2026 revenue guidance to between $460 million and $470 million. Total revenue grew 47% year over year to $123 million, marking the fifth consecutive quarter of positive operating income under generally accepted accounting principles (GAAP, standard accounting rules). Higher average selling prices (ASP, the average revenue collected per test) and growing oncology volume prove that its testing platform scales profitably. Three key takeaways stand out for long-term investors. BillionToOne plans to launch Northstar Clear on Dec. 15, 2026, to expand into minimal residual disease (MRD, testing that detects trace cancer cells in blood). The assay requires only a blood draw and avoids physical tumor tissue samples entirely. A published head-to-head study demonstrated that Northstar Response matched or beat a leading tissue-dependent test for monitoring treatment response. Removing the need for physical tissue eliminates processing delays and lowers test failure rates for oncologists. Continue reading

Read original article